Tests on a new COVID vaccine in the UK have so far shown it produces a “strong immune response”, Health Secretary Matt Hancock has said.
The Valneva COVID-19 vaccine is being developed in Livingston, Scotland, and data from an early-stage phase one/two study involving 153 people showed promising results for the jab, paving the way for a phase three clinical trial.
The vaccine was safe and generally well tolerated, with no safety concerns identified by an independent data safety monitoring board.
The company said the results showed the vaccine was “highly immunogenic with more than 90% of all study participants developing significant levels of antibodies” to the COVID virus spike protein.
